{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T19:59:33Z","timestamp":1777492773025,"version":"3.51.4"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T00:00:00Z","timestamp":1699228800000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,11,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>Dapagliflozin has been widely used for the treatment of type 2 diabetes mellitus (T2DM) and heart failure (HF). However, data concerning the association between dapagliflozin and the recurrence of atrial fibrillation (AF), especially in patients following Cox-Maze IV (CMIV), are rare. We aim to explore the effect of dapagliflozin on the recurrence of AF after CMIV with and without T2DM or HF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>The study of dapagliflozin evaluation in AF patients followed by CMIV (DETAIL-CMIV) is a prospective, double-blind, randomized, placebo-controlled trial. A total of 240 AF patients who have received the CMIV procedure will be randomized into the dapagliflozin group (10\u2005mg\/day, n = 120) and the placebo group (10\u2005mg\/day, n = 120) and treated for 3 months. The primary endpoint is any documented atrial tachyarrhythmia (AF, atrial flutter or atrial tachycardia) lasting 30\u2005s following a blanking period of 3 months after CMIV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>DETAIL-CMIV will determine whether the sodium-glucose cotransporter-2 inhibitor dapagliflozin, added to guideline-recommended post-operative AF therapies, safely reduces the recurrence rate of AF in patients with and without T2DM or HF.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/europace\/euad333","type":"journal-article","created":{"date-parts":[[2023,11,9]],"date-time":"2023-11-09T00:11:54Z","timestamp":1699488714000},"source":"Crossref","is-referenced-by-count":4,"title":["Rationale and design of a randomized trial of the dapagliflozin evaluation on atrial fibrillation patients followed Cox-Maze IV: the DETAIL-CMIV study"],"prefix":"10.1093","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4621-1968","authenticated-orcid":false,"given":"Zhan","family":"Peng","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Vessel Disease , 2# Anzhen Road, Cao Yang District, Beijing 100029 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Osmanaj","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Vessel Disease , 2# Anzhen Road, Cao Yang District, Beijing 100029 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-2484","authenticated-orcid":false,"given":"Yunxiao","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Vessel Disease , 2# Anzhen Road, Cao Yang District, Beijing 100029 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2189-3632","authenticated-orcid":false,"given":"Kun","family":"Hua","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Vessel Disease , 2# Anzhen Road, Cao Yang District, Beijing 100029 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2318-5227","authenticated-orcid":false,"given":"Xiubin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Vessel Disease , 2# Anzhen Road, Cao Yang District, Beijing 100029 , China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,6]]},"reference":[{"key":"2023111711150947400_euad333-B1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0140-6736(14)61774-8","article-title":"50 Year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study","volume":"386","author":"Schnabel","year":"2015","journal-title":"Lancet"},{"key":"2023111711150947400_euad333-B2","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart disease and stroke statistics-2019 update: a report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"2023111711150947400_euad333-B3","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41572-022-00347-9","article-title":"Atrial fibrillation","volume":"8","author":"Brundel","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"2023111711150947400_euad333-B4","first-page":"1","article-title":"Electrophysiologic basis, surgical development, and clinical results of the maze procedure for atrial flutter and atrial fibrillation","volume":"6","author":"Cox","year":"1995","journal-title":"Adv Card Surg"},{"key":"2023111711150947400_euad333-B5","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.hrthm.2011.12.016","article-title":"2012 HRS\/EHRA\/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design: a report of the Heart Rhythm Society (HRS) task force on catheter and surgical ablation of atrial fibrillation","volume":"9","author":"Calkins","year":"2012","journal-title":"Heart rhythm"},{"key":"2023111711150947400_euad333-B6","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/ejcts\/ezx326","article-title":"The Cox-Maze IV procedure in its second decade: still the gold standard?","volume":"53","author":"Ruaengsri","year":"2018","journal-title":"Eur J Cardiothorac Surg"},{"key":"2023111711150947400_euad333-B7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s11748-011-0849-2","article-title":"Surgery for atrial fibrillation: recent progress and future perspective","volume":"60","author":"Nitta","year":"2012","journal-title":"Gen Thorac Cardiovasc Surg"},{"key":"2023111711150947400_euad333-B8","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S2213-8587(16)00052-8","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis","volume":"4","author":"Wu","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023111711150947400_euad333-B9","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","article-title":"Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial","volume":"141","author":"Zelniker","year":"2020","journal-title":"Circulation"},{"key":"2023111711150947400_euad333-B10","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1007\/s10741-022-10281-3","article-title":"Association between sodium-glucose cotransporter-2 inhibitors and incident atrial fibrillation\/atrial flutter in heart failure patients with reduced ejection fraction: a meta-analysis of randomized controlled trials","volume":"28","author":"Sfairopoulos","year":"2023","journal-title":"Heart Fail Rev"},{"key":"2023111711150947400_euad333-B11","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12933-020-01105-5","article-title":"SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials","volume":"19","author":"Li","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2023111711150947400_euad333-B12","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1016\/j.jacep.2022.08.004","article-title":"Efficacy of sodium-glucose cotransporter 2 inhibitors on outcomes after catheter ablation for atrial fibrillation","volume":"8","author":"Kishima","year":"2022","journal-title":"JACC Clin Electrophysiol"},{"key":"2023111711150947400_euad333-B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-022-07368-2","article-title":"Effect of dapagliflozin on the outcome of radiofrequency catheter ablation in patients with type 2 diabetes mellitus and atrial fibrillation","author":"Luo","year":"2022","journal-title":"Cardiovasc Drugs Ther"},{"key":"2023111711150947400_euad333-B14","doi-asserted-by":"crossref","first-page":"898642","DOI":"10.3389\/fcvm.2022.898642","article-title":"Effect of preablation glycemic control on outcomes of atrial fibrillation patients with diabetes mellitus following valvular surgery combined with the Cox-Maze IV procedure","volume":"9","author":"Peng","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"2023111711150947400_euad333-B15","doi-asserted-by":"crossref","first-page":"443","DOI":"10.4070\/kcj.2019.0296","article-title":"Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2 (SGLT- 2) inhibitor in a normoglycemic rabbit model","volume":"50","author":"Lee","year":"2020","journal-title":"Korean Circ J"},{"key":"2023111711150947400_euad333-B16","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12933-018-0790-0","article-title":"A SGLT2 inhibitor dapagliflozin suppresses prolonged ventricular repolarization through augmentation of mitochondrial function in insulin-resistant metabolic syndrome rats","volume":"17","author":"Durak","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2023111711150947400_euad333-B17","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"key":"2023111711150947400_euad333-B18","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","article-title":"Dapagliflozin attenuates Na(+)\/H(+) exchanger-1 in cardiofibroblasts via AMPK activation","volume":"32","author":"Ye","year":"2018","journal-title":"Cardiovasc Drugs Ther"},{"key":"2023111711150947400_euad333-B19","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jacbts.2019.11.007","article-title":"SGLT2 inhibitor-induced sympathoinhibition: a novel mechanism for cardiorenal protection","volume":"5","author":"Herat","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"2023111711150947400_euad333-B20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s12933-017-0658-8","article-title":"The effect of dapagliflozin treatment on epicardial adipose tissue volume","volume":"17","author":"Sato","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2023111711150947400_euad333-B21","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","article-title":"Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis","volume":"5","author":"Birkeland","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023111711150947400_euad333-B22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1111\/dom.13077","article-title":"Dapagliflozin is associated with lower risk of cardiovascular events and all-cause mortality in people with type 2 diabetes (CVD-REAL Nordic) when compared with dipeptidyl peptidase-4 inhibitor therapy: a multinational observational study","volume":"20","author":"Persson","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2023111711150947400_euad333-B23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1177\/2047487318755531","article-title":"Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: a systematic review and meta-analysis","volume":"25","author":"Usman","year":"2018","journal-title":"Eur J Prev Cardiol"},{"key":"2023111711150947400_euad333-B24","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s12933-020-01162-w","article-title":"The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors","volume":"19","author":"Ling","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"2023111711150947400_euad333-B25","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2337\/dc22-0714","article-title":"Sodium-glucose cotransporter 2 inhibitor treatment and risk of atrial fibrillation: scandinavian cohort study","volume":"46","author":"Engstr\u00f6m","year":"2023","journal-title":"Diabetes Care"},{"key":"2023111711150947400_euad333-B26","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/dom.14211","article-title":"Sodium-glucose co-transporter-2 inhibitors and atrial fibrillation in the cardiovascular and renal outcome trials","volume":"23","author":"Okunrintemi","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2023111711150947400_euad333-B27","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","article-title":"Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta analysis of 34 randomized controlled trials","volume":"18","author":"Fernandes","year":"2021","journal-title":"Heart Rhythm"},{"key":"2023111711150947400_euad333-B28","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12933-021-01293-8","article-title":"Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis","volume":"20","author":"Li","year":"2021","journal-title":"Cardiovasc Diabetol"}],"container-title":["Europace"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/europace\/advance-article-pdf\/doi\/10.1093\/europace\/euad333\/52934803\/euad333.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/11\/euad333\/53479530\/euad333.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/europace\/article-pdf\/25\/11\/euad333\/53479530\/euad333.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T13:33:40Z","timestamp":1700228020000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/europace\/article\/doi\/10.1093\/europace\/euad333\/7367867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,2]]}},"URL":"https:\/\/doi.org\/10.1093\/europace\/euad333","relation":{},"ISSN":["1099-5129","1532-2092"],"issn-type":[{"value":"1099-5129","type":"print"},{"value":"1532-2092","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,11]]},"published":{"date-parts":[[2023,11]]},"article-number":"euad333"}}